Subscribe

August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights

View Additional ASCO 2019 Coverage

Disparities in Oncology
ASCO 2019 Presidential Address: Removing Disparities in Cancer Care
Wayne Kuznar
Read More
Renal-Cell Carcinoma
Avelumab plus Axitinib New First-Line Standard of Care in Advanced Renal-Cell Carcinoma
Chase Doyle
Read More
Disparities in Oncology
Access to Health Insurance Reduces Disparities in Cancer Care: The Case for the ACA
Phoebe Starr
Read More
Prostate Cancer
Enzalutamide or Apalutamide Added to ADT Improves Outcomes in Hormone-Sensitive Prostate Cancer
Phoebe Starr
Read More
FDA Approvals
Polivy FDA Approved for Patients with Relapsed or Refractory DLBCL
Read More
FDA Approvals
Xpovio Receives FDA Approval for Patients with Relapsed or Refractory Multiple Myeloma
Read More
FDA Approvals
Revlimid Approved for Patients with Follicular Lymphoma or Marginal-Zone Lymphoma
Read More
FDA Approvals
Keytruda First PD-1 Inhibitor Approved as First-Line Monotherapy for Patients with Metastatic or Unresectable Head and Neck Cancer
Read More
FDA Approvals
Keytruda Receives New Indication for Metastatic Small-Cell Lung Cancer After Disease Progression
Read More
FDA Approvals
Darzalex Combined with Revlimid and Dexamethasone New First-Line Regimen for Patients with Multiple Myeloma Ineligible for Transplant
Read More
Page 1 of 3
Results 1 - 10 of 30
Copyright © Engage Healthcare Communications, LLC. All rights reserved.